Celgene
In February 2008, Acceleron entered into a worldwide strategic collaboration with Celgene Corporation for the joint development and commercialization of sotatercept (ACE-011). In August, 2011, Acceleron and Celgene expanded the collaboration to include a second product, ACE-536. In total, Acceleron has received over $100 million from Celgene in license fees, milestones, cost sharing, and for the purchase of equity. Acceleron and Celgene will collaborate to develop both sotatercept and ACE-536 and potentially other products for treating anemia across a wide range of indications. Acceleron is eligible to receive up to $367 million in milestone payments for the sotatercept program and up to $217M for the ACE-536 program. Acceleron will pay a share of development expenses through the end of 2012 for both programs and Celgene will be responsible for all costs thereafter. Acceleron will receive royalty payments on worldwide product sales and Acceleron and Celgene will co-promote the products in North America.
For ACE-536, Acceleron will be responsible for conducting the Phase 1 and initial Phase 2 clinical trials and Celgene will conduct the subsequent Phase 2 and Phase 3 clinical studies. Acceleron will manufacture product for the Phase 1 and Phase 2 clinical trials and Celgene will have responsibility for the manufacture of Phase 3 and commercial supplies.